By the efforts of the biotechnology development headquarter, 22 biomedicines have been produced in Iran, which were formerly imported from other countries. These complicated biomedicines are produced by the efforts of domestic experts and with the support of the Vice-Presidency.

According to the public relations and information center of the Vice-Presidency for science and technology affairs, one of the priorities of the biotechnology development headquarter is supporting domestic production of biomedicine, which are supplied at a high cost from other countries. Supplying these drugs has been associated with a high rate of currency exit from the country. In addition, patients have faced many problems in purchasing of these drugs.

Support of Production of 20 Biomedicines

Mostafa Ghanei, secretary of biotechnology development headquarter, expressed about the production of new biomedicine in the country: one of the priorities of the biotechnology development headquarter is supporting the production of new drugs. It is aimed to produce 20 new biomedicines in the country in the next four years.

He added: currently, there are 146 biomedicines in the global market, 22 of which are available in Iran, including monoclonal antibody and some recombinant drugs. According to Ghanei, the number of biomedicines will increase to 40 drugs by producing new medications.